(NASDAQ: LQDA) Liquidia's forecast annual revenue growth rate of 180.1% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.57%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.38%.
Liquidia's revenue in 2025 is $14,144,000.On average, 4 Wall Street analysts forecast LQDA's revenue for 2025 to be $3,640,956,889, with the lowest LQDA revenue forecast at $2,504,696,583, and the highest LQDA revenue forecast at $4,411,856,335. On average, 4 Wall Street analysts forecast LQDA's revenue for 2026 to be $17,518,771,131, with the lowest LQDA revenue forecast at $11,513,910,672, and the highest LQDA revenue forecast at $26,278,797,830.
In 2027, LQDA is forecast to generate $26,569,445,215 in revenue, with the lowest revenue forecast at $17,993,637,667 and the highest revenue forecast at $36,177,050,980.